Merck & Co. (MRK)
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-09-04
$150.33-1.32%
Close 2026-09-04 · 1-day change
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-09-04
QuarterlyIQ Insights · MRK
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 71.4% |
| Our one-year growth estimate | diamond | 4.1% |
Growth built into the price is above our model estimate.
The price assumes 67.3 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Model as of 2026-09-04 · Compared with 10 industry peers
Review the full earnings evidenceWhy it matters: Keeping EPS guidance shows trust in future earnings, even with current losses.
Supportive ifManagement maintains EPS guidance of $5.04-$5.16 for 2026 despite losses.
Worry ifManagement lowers EPS guidance to $5.04-$5.16 for 2026.
Why it matters: Sales growth over 5% would show the company can meet its higher revenue goals.
Supportive ifQ2 worldwide sales were over $17.1 billion. This shows more than 5% growth.
Worry ifQ2 worldwide sales were below $16.5 billion. This means growth is weaker.
Why it matters: Changes in management's guidance can show confidence in earnings. A revision may show how well the company manages costs and growth.
Watch forManagement raises non-GAAP EPS guidance above $2.76 for Q3.
Also watch forManagement lowers non-GAAP EPS guidance below $2.66 for Q3.
Why it matters: If EPS falls below this forecast, it may show profit challenges despite revenue growth.
Worry ifNon-GAAP EPS reported below $5.04 for 2026.
Less concerning ifNon-GAAP EPS reported at $5.04 or higher for 2026.
Why it matters: If sales growth drops below this level, it may mean less demand for KEYTRUDA.
Worry ifQ2 2026 total sales growth reported below 5% year over year.
Less concerning ifQ2 2026 total sales growth reported above 5% year over year.
Why it matters: Raising revenue guidance shows stronger sales and growth potential.
Supportive ifManagement raises revenue guidance in the next earnings call.
Worry ifRevenue guidance remains unchanged or is lowered in the next earnings call.
Why it matters: If this drug is approved, it will grow Merck's blood disease treatments and open new areas.
Supportive ifFDA approves TERN-701 before the expected end of the acquisition.
Worry ifFDA denies approval or delays the decision on TERN-701.
Why it matters: Updates on oncology drugs can impact future sales and growth. Positive news may boost investor confidence.
Supportive ifPositive results from a Phase 3 trial for any oncology drug in the pipeline.
Worry ifThere are trial failures or delays in the oncology pipeline.
Why it matters: This acquisition could strengthen Merck's blood disorder drug pipeline and growth plans.
Supportive ifThe Terns Pharmaceuticals acquisition should finish by the end of May 2026.
Worry ifAcquisition not completed by the end of May 2026.
Why it matters: An increase in guidance shows confidence in sales growth and pipeline performance.
Supportive ifManagement raises revenue guidance for the year to over $67.3 billion.
Worry ifManagement keeps or lowers revenue guidance for the year to under $66.3 billion.
Why it matters: The deal could improve Merck's hematology pipeline and growth. Investors will look at its effect on earnings.
Supportive ifThe Terns Pharmaceuticals deal is done with positive comments on its strategy.
Worry ifDelays or negative comments about the deal's effect on Merck's strategy.
Why it matters: Earnings results will show how Merck is doing and what to expect.
Watch forEarnings beat expectations, showing strong growth.
Also watch forEarnings did not meet expectations. This may show problems with growth.
Why it matters: Good data from these trials could help Merck's cancer treatments and boost future sales.
Supportive ifSuccessful Phase 3 data readouts from at least two oncology trials.
Worry ifBad Phase 3 data from any cancer trial.
Why it matters: KEYTRUDA is important for revenue. Its growth helps the company's cancer treatment plan and sales.
Supportive ifKEYTRUDA sales grow year over year by more than 5%.
Worry ifKEYTRUDA sales decline year over year or grow less than 5%.
Why it matters: New FDA approvals can improve the oncology pipeline. They are key for staying competitive.
Supportive ifAnnouncement of FDA approval for at least one new oncology drug.
Worry ifNo new FDA approvals for oncology drugs in the next quarter.
Why it matters: Growth in Animal Health is a key priority. Strong performance can indicate successful product launches and market demand.
Supportive ifAnimal Health sales increase year over year by more than 8%.
Worry ifAnimal Health sales decline year over year or grow less than 5%.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$111 on $10,000 · ±1.1% | How much price usually moves either way. |
| Bad day | $243 loss on $10,000 · 2.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $1,137 loss on $10,000 · 11.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.